ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Anne Carter
Louis E. Samuels
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petrucci, R. J.
Right arrow Articles by Narula, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petrucci, R. J.
Right arrow Articles by Narula, J.
Related Collections
Right arrow Mechanical Circulatory Assistance

Ann Thorac Surg 2006;81:1738-1744
© 2006 The Society of Thoracic Surgeons

Original article: Cardiovascular

Cognitive Dysfunction in Advanced Heart Failure and Prospective Cardiac Assist Device Patients

Ralph J. Petrucci, EdD a , * , Karen C. Truesdell, PhD b , Anne Carter, PhD a , Naomi E. Goldstein, PhD b , Megan M. Russell, MS b , Danielle Dilkes, PhD b , Jane M. Fitzpatrick, MD a , Carole E. Thomas, MD a , Margaret E. Keenan, PhD c , Lewis A. Lazarus, PhD d , Nancy D. Chiaravalloti, PhD e , Joseph J. Trunzo, PhD f , Johan W. Verjans, MS h , Elena C. Holmes, CRNP g , Louis E. Samuels, MD g , Jagat Narula, MD, PhD h

a College of Medicine, Drexel University, Philadelphia, Pennsylvania
b Department of Clinical and Health Psychology, Drexel University, Philadelphia, Pennsylvania
c Behavioral Medicine, Christiana Care Health System, Wilmington, Delaware
d Voorhees, New Jersey
e Neuropsychology Department, Kessler Rehabilitation Research and Educational Corporation, West Orange, New Jersey
f Psychology Department, Bryant College, Smithfield, Rhode Island
g Cardio-Thoracic Surgery, Lankenau Hospital, Wynnewood, Pennsylvania
h College of Medicine, University of California-Irvine, Irvine, California

Accepted for publication December 2, 2005.

* Address correspondence to Dr Petrucci, Drexel University College of Medicine, Psychiatry and Medicine, 245 N 15th Street, MS 115, Philadelphia, PA 19102 (Email: ralph.petrucci{at}drexelmed.edu).


   Abstract
Top
 Abstract
Introduction
 Patients and Methods
 Results
 Comment
 References
 
BACKGROUND: Extended periods of hypoperfusion in an advanced heart failure (HF) places patients at high risk for neurobehavioral compromise, which has not been studied systematically. It is also not clear how intravenous inotropic therapy and mechanical cardiac assist devices (MCAD) affect cognitive function.

METHODS: This prospective cross-sectional cognitive preliminary study evaluated 252 potential heart transplant candidates assessing functions in memory, motor, and processing speed. Patients were divided into three HF groups based on severity of disease: group 1 outpatients (n = 113), group 2 in-patients requiring inotropic infusion (n = 83), and group 3 inpatients likely requiring MCAD support (n = 56). Aggregate z-scores for memory, motor, and processing speed and independent samples t tests assessed intergroup differences on 13 cognitive measures.

RESULTS: A broad pattern of cognitive impairment was observed within the advanced HF group; fewer deficits were found in group 1 outpatients and more severe deficits in group 3 MCAD subjects. A difference in motor functions was observed as the earliest abnormality, with group 3 showing significant changes compared with group 1. The most dramatic changes were seen in domain mental processing speed along with specific verbal and visual memory functions, which were slower in group 3 compared with groups 1 and 2.

CONCLUSIONS: Cognitive deficits are common in advanced HF and worsen with increasing severity of HF. Appropriately designed and randomized studies will be needed to demonstrate if earlier MCAD implantation is warranted to arrest cognitive dysfunction and better postimplantation adaptation.


   Introduction
Top
 Abstract
 Introduction
Patients and Methods
 Results
 Comment
 References
 
Advanced or end-stage heart failure (HF) is associated with a high rate of morbidity and mortality. Patients with end-stage HF are often maintained on inotrope infusion or more recently on mechanical cardiac assist devices (MCAD) until a definitive intervention such as cardiac transplantation is offered. Because the comprehensive impact of cardiac transplantation is limited owing to the lack of ample organ availability [1], use of MCAD is consistently increasing as a destination therapy [2, 3].

It is assumed that low cardiac output in advanced HF leads to renal and hepatic dysfunction. The impact of long-term cardiac insufficiency on the function of end organs highlights the need to intervene before the end-organ damage sets in. While it is now increasingly recognized that low cardiac output also adversely affects neurobehavioral functions through decreased blood flow, this may also need to be evaluated in advanced HF. The quality of neurobehavioral performance significantly influences functional independence after MCAD placement [4, 5]; and therefore, it is critical to assess the cognitive ability of the patients to manage a bridge or destination device [6]. The cognitive performance of device aspirants or recipients has not been adequately studied and compared with other modes of management strategies in advanced HF [7]

Neuropsychological assessment has been commonly performed and has revealed frequent cognitive impairment in coronary bypass and transplant recipients [8, 9]. Preprocedure and postprocedure measures have shown a range of cognitive deficits [10–13], and the postoperative behavioral adjustment in such patients is significantly influenced by neurobehavioral function before surgery [14–18]. Earlier studies of pretransplant cognitive assessment have demonstrated moderate to severe impairment in up to 60% of patients with heart failure [19–22]. Ischemic stress, as a consequence of heart failure, has been shown to contribute to cognitive deficits including attention deficit and total and delayed memory recall impairment [23, 24].

The present prospective investigation involved a baseline comparison of cognitive functions obtained during initial transplant evaluation in a large patient population with variable degrees of advanced HF. The cohort included transplant evaluations in outpatients or during hospitalization in patients requiring intravenous inotropic therapy or prospective MCAD placement.


   Patients and Methods
Top
 Abstract
 Introduction
 Patients and Methods
Results
 Comment
 References
 
Patients
This 18-year cross sectional study, from January 1984 to December 2002, evaluated a total of 710 end-stage HF patients who were New York Heart Association (NYHA) stage III to IV symptomatic, had left ventricular ejection fraction of less than 20%, and required frequent hospitalizations for worsening heart failure. Patients who met inclusion criteria were all potential candidates for heart transplantation at two transplant centers and were classified into one of three categories. Group 1 consisted of 301 patients not requiring intravenous inotropic support who were examined in the office as outpatients. All group 1 patients received the optimal HF therapeutic regimen as recommended by the prevailing HF management guidelines. Group 2 consisted of 303 patients requiring admission for intravenous inotropic therapy who underwent transplant evaluation as inpatients. Patients in this group were evaluated within a week after the initiation of intravenous inotropes. The remaining 106 unstable inpatients on inotropes were considered for MCAD (group 3). They were examined within 3 hours to 5 days before scheduled implant.

Inclusion for the neuropsychological examination required patients to sit up in bed, maintain an arterial oxygen saturation of greater than 90%, and provide verbal consent. These patients were not considered for randomized medication versus device trials. Criteria were met by 113 group 1, 83 group 2, and 56 group 3 patients (Table 1), and they form the basis of the present report. Although all potential transplant candidates undergo neurobehavioral evaluation, only 37% patients could complete the tests for enrollment; this study, therefore, does not fulfill the criteria for consecutive recruitment. Patients of groups 2 and 3 were examined in the hospital while on telemetry monitoring. Twenty-nine of the 56 group 3 patients received MCAD support (Thoratec-11, Thoratec Corp, Pleasanton, CA; Abiomed-8, Abiomed Inc, Danvers, MA; Novacor-9, World Heart Inc, Oakland, CA; and AbioCor-1, Abiomed Inc) before transplant. Seventeen of the 29 device patients went on to receive transplantation, and 1 patient received a totally implantable artificial heart; 11 patients died before transplant. Patients remained in their initial respective groups and were not reexamined or moved into another group with the progression of their cardiac disease. There were no controls established for medications, hemodynamics, or concomitant medical disease. Over the 18 years of recruitment for the study, major changes have occurred in management of heart failure that may have inadvertently impacted the outcomes of this study. A retrospective data review with individual consent waived was approved by the Institutional Review Board (University Project 1000547) on May 18, 2000. Individual verbal consent was obtained at time of testing.


View this table:
[in this window]
[in a new window]
  		Table 1. Patient Demographics in End-Stage Heart Failure (ESHF) Groups
 
The 252 patients in groups 1, 2, and 3 had mean ages of 46, 50, and 52 years, respectively, with males comprising 81%, 78%, and 84%, respectively (Table 1). Although no significant group differences were found between age and education, the proportion of ischemic cardiomyopathy in group 3 MCAD subjects was lower (p < 0.05). A history of neurologic events was recorded during the initial presentation in 16%, 24%, and 21% of cases for groups 1, 2, and 3, respectively. The neurologic events included cerebrovascular accident or transient ischemic attack (82%), seizure (12%), significant head trauma as defined by loss of consciousness or amnesia (4%), and encephalitis and neoplasm (2%). If the nature of the neurologic event was unclear, the patient or family was asked to identify medical treatment or hospitalization. Syncopal episodes, arrhythmias, and carotid artery disease were not recorded. Significant neurologic conditions could exclude patients from cardiac candidacy or device implantation.

Neuropsychological Examination
The neuropsychological measures were selected for ease of administration with these advanced HF patients. A 45- to 60-minute bedside testing session was designed to survey 13 cognitive functions and was administered in standard fashion to all groups. Testing was conducted once during the initial presentation within each group. The measures were divided into three broad domains: memory, motor functions, and processing speed.

The memory evaluation included the administration of the Wechsler Memory Scale (WMS) [25], the Benton Visual Retention Test (Benton VRT; Administration A–Form C) [26], and the Rey Auditory Verbal Learning Test (Rey AVLT) [27]. The WMS is composed of subtests measuring verbal and visual memory ability with immediate and 30-minute delayed recall procedures. Verbal memory was assessed by asking the patient to recall two short stories verbatim. Visual memory tests required the patient to recall and reproduce three designs. The WMS yields separate normally distributed scores for verbal and visual memory. The Benton VRT has single or multiple designs for recall that are scored for the number correct and error quality. Fifteen words are presented verbally in the Rey AVLT over five trials, followed by an additional trial in which a nonsense list is introduced for distraction. The total number of original words recalled from 6 trials is scored. Motor function was evaluated with a finger-tapper and hand-grip dynamometer [28]. The mean number of finger taps in a predefined time period and the mean grip strength in kilograms were separately recorded for dominant and nondominant hands. Mental processing speed was measured through administration of the Trail Making Tests A and B [28]. Trail Making A requires the patient to draw a line between sequential numbers, and Trail Making B requires the patient to draw a line alternating sequentially between circled numbers and letters.

Statistical Analysis
Aggregate z-scores were created for three major cognitive domains: memory (with verbal and visual subsets), motor function, and processing speed. The z-scores were used to standardize data for analyses. Independent sample t tests were performed to assess intergroup differences between groups 1, 2, and 3 HF patients. Controlling for individual variables was not included in this design. The confidence level was established at p less than 0.05 for all functions with equality of variances considered for each analysis. Under these three major categories, 13 individual cognitive measures were evaluated. Independent samples t tests were performed for the 13 individual cognitive measures between groups 1, 2, and 3 (Table 2). Bonferroni corrections were applied for the three domains (p < 0.017) and the 13 cognitive measures (p < 0.004). The severity of the cardiac illness prevented some patients from completing all 13 cognitive measures; consequently sample size may differ across analyses.


View this table:
[in this window]
[in a new window]
  		Table 2. Comparison of Cognitive Measures, Individual t Tests Among Inpatients and Outpatients, and Prospective MCAD Patients
 

   Results
Top
 Abstract
 Introduction
 Patients and Methods
 Results
Comment
 References
 
Overall Trends of Cognitive Dysfunction
Varying levels of cognitive impairment were observed within the domains, with fewer deficits found in group 1 outpatients and more severe deficits in group 3 patients who required MCAD. The most dramatic change was seen in the domain involving mental processing speed, specifically comparing group 1 with 3 and group 2 with 3. A similar but less dramatic trend was evident with verbal and visual memory. On the other hand, whereas motor deficits occurred early, only significant differences were observed between groups 1 and 3 (Fig 1).


Figure 1
View larger version (42K):
[in this window]
[in a new window]
  		Fig 1. Means for all levels of end-stage heart failure for (left) memory, (center) motor, and (right) processing (proc.) speed. *p < 0.017. White circles = group 1; light gray circles = group 2; dark gray circles = group 3; vs = versus.

 
Verbal and Visual Memory
Memory functions across all groups were deficient as demonstrated with group 3 scoring significantly lower when compared with either group 1 or 2 (Fig 2A, B). This level of cognitive dysfunction was more evident in WMS verbal delayed memory, Benton VRT number correct, and Rey AVLT total retention. An exception was observed in WMS immediate visual memory group 3 with wide standard deviations. All tests of memory reflected similar performance levels of declining memory as seen within WMS verbal delay, WMS visual immediate and delay, Benton VRT number correct, and Rey AVLT total recall immerging as the most discriminating memory deficit measures.


Figure 2
View larger version (61K):
[in this window]
[in a new window]
  		Fig 2. Group means for the cognitive domains of end-stage heart failure for (A, B) memory, (C) motor, and (D) processing speed. *p < 0.004. White circles = group 1; light gray circles = group 2; dark gray circles = group 3. (BVRT = Benton Visual Retention Test; Corr. = correct; d = dominant hand; Err. = error; Immed = immediate; n-d = non-dominant hand; RAVLT = Rey Auditory Verbal Learning Test; Tot. = total; Verb. = verbal; Vis. = visual; vs = versus; WMS = Wechsler Memory Scale.)

 
Motor Function
Reduced motor speed and grip strength was evident early in end-stage heart failure when compared with other cognitive dysfunctions; significant differences were found between groups 1 and 3 (Fig 2C). The dominant hand finger-tapping test demonstrated the most significant decline in motor function. Many patients were not able to complete grip strength testing because of pain caused by infusion lines and the extent of physical deconditioning.

Mental Processing Speed
Mental processing speed was seen to decline across the three groups with increasing severity (Fig 2D). Processing speed was slower for group 3 than groups 1 and 2. Although group 2 scored below group 1 on Trail Making B, the difference was not significant. Processing speed, as measured by Trail Making A and B, appears to get slower in each group. The performance of group 3 was slower than the other groups in this cognitive domain; however, it only approached significance after the Bonferroni correction. The time for the MCAD group Trail Making A and B performance was more than 1 and 2 minutes, respectively, differentiating this group from other patients.


   Comment
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Comment
References
 
Cognitive Dysfunction in Advanced HF
This preliminary study, involving a cross section of patients with advanced HF, suggests a decline in global cognitive performance is influenced by the progressive severity of heart failure. Cognitive domains of group 1 outpatients compared with group 2 and 3 hospitalized patients revealed motor functions were affected earlier. As the disease advances, verbal recall, visual memory, and then mental processing speed are affected (Table 2). Greater cognitive disruptions became evident within the MCAD patients. When individual cognitive functions were compared across groups after the Bonferroni correction, 4 of the 13 measures showed extended or more pronounced levels of impairment in the MCAD group when compared with the outpatients. When group 3 was compared with the inpatients receiving inotropes, 2 of 13 measures reflected more advanced cognitive performance deficits. These cognitive changes reflected cerebral dysfunction in critical areas involving immediate and delayed memory, consolidation, and visual integration. Age, an important confounding variable reported in previous studies, was not found to be significant in this study because of wide standard deviations in groups [19, 24, 29].

Possible Mechanisms of Cognitive Dysfunction
A number of factors may contribute alone or in combination to neurobehavioral deficits in the advanced HF population. Whereas the low cardiac output is known to contribute to the cognitive abnormalities [29, 30], it is conceivable that systolic hypotension and ischemia in the absence of cerebrovascular events [31] may add to neurobehavioral dysfunction, with the role of hypotension particularly important in women [32–35]. Patients with HF have been shown to experience losses in cerebral grey matter in the mesial temporal lobe, including the hippocampus and parahippocampus, regions particularly sensitive to hypoxia and accountable for memory changes. Brain volumetric analysis shows associated grey matter loss in regions involving the insula, basal ganglia, cerebellum, dorsal midbrain, and frontal regions [36]. Further, the use of intravenous inotropic agents may complicate a cognitive disturbance; these agents have significant apoptogenic and necrotogenic potential and may inflict direct damage. Inotropic agents such as dobutamine are known to lead to myocellular toxicity [37, 38]; however, any parallel effects on neurobehavioral functioning in this study in the absence of controls is speculative.

Potential Clinical Implications of Cognitive Dysfunction
The present study raises an important question. Should assist devices be offered to patients sooner, that is, before they develop the progressive neurobehavioral compromise? Assessing presurgical cognitive compromise as outlined by the Food and Drug Administration mandate [39] is especially important as devices take on a more prominent role in destination therapy and with irreversible cognitive decline a likely relative contraindication [40]. Since there is growing evidence to show left ventricular mechanical support offers greater improvement with heart failure symptoms compared with inotropic therapy, and as observed in the present study if early mechanical support spares further cognitive decline, it may be prudent to recommend MCAD implantation as soon as there is relative evidence of deficits in mental processing speed and memory function deterioration begin to appear. Although MCAD implantation may offer an increased degree of cognitive stability, microemboli will continue to remain a threat. A longitudinal design would assist with the understanding of important variables, such as monitoring microembolic events and whether early MCAD placement leads to cognitive decline, stabilization, or improvement. The question of whether avoiding prolonged inotropic support by earlier MCAD implantation and thereby preventing further cognitive compromise needs consideration.

Limitations of the Study
Many of the sicker HF patients could not complete the entire neuropsychological battery for a number of medically related reasons. Testing was completed by the most able of this sick population. Only those with complete data could be included in the analysis, thus decreasing sample size and inducing selection bias. The second limitation of the study involves the lack of controls for medications, hemodynamics, or comorbid medical conditions. Any and all of these factors can influence neurobehavioral outcomes. The inclusion criteria were limited to NYHA class III to IV symptoms, an ejection fraction less than 20%, heart transplant candidacy, and without controls. The third limitation results from having less than 20% female patients in our study population, albeit this roughly represents the number of women with heart failure. Fourth, heart failure treatment regimes have changed over the 18-year period, further confounding the design beyond our control. Fifth, there was no premorbid cognitive parameter available for comparison at the time of the neuropsychological testing except for the educational history. Sixth, given the prevalence of ischemic heart disease in this group, the findings from transesophageal echocardiography and vascular studies to detect cerebral emboli would be appropriate. Lastly, we have not provided another study group for cognitive comparison such as a cardiac bypass population or patients with another chronic noncardiac disease process. Without a cross-group comparison, findings from the present study cannot be interpreted as unique to the advanced HF population. This limitation also may not allow exclusion of the confounding effects of use of sedatives, physical deconditioning, and transitional metabolic alterations. Despite the limitations, this is a cross-sectional cognitive study comparing prospective MCAD patients with other HF cohorts.

Suggested Cognitive Screening With This Cardiac Group
As a result of this research, it is clear that modifications to standard cognitive protocols should be implemented with this fragile population. A brief screening battery is suggested because of the patient's physical condition and time limitations. We suggest that auditory and visual memory functions with delayed procedures (WMS) in combination with processing speed and executive abilities (Trail Making) are essential components. Isolated motor functions should be eliminated. Reviewing language functions and spatial processing should be added.

Does Cognitive Dysfunction Represent Yet Another End-Organ Dysfunction?
Despite these limitations, we consider these results substantially informative, adding to our understanding of neurobehavioral perturbations in patients with advanced HF. Our ongoing research involves a larger sample size with control groups, serial cognitive testing before and after implant, corroborative family information, and longitudinal follow-up. It is possible that the cognitive dysfunction represents another end-organ dysfunction in advanced HF. If it is demonstrated that MCAD implantation can arrest progressive neurobehavioral decline, decisions for earlier intervention would become logical.


   References
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Comment
 References
 

  1. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure N Engl J Med 2001;345:1435-1443.[Abstract/Free Full Text]
  2. Catanese KA, Goldstein DJ, Williams DL, et al. Outpatient left ventricular assist device supporta destination rather than a bridge. Ann Thorac Surg 1996;62:646-653.[Abstract/Free Full Text]
  3. McCarthy PM, Smedira NO, Vargo RL, et al. One hundred patients with the HeartMate left ventricular assist deviceevolving concepts and technology. J Thorac Cardiovasc Surg 1998;115:904-912.[Abstract/Free Full Text]
  4. Oz MC, Argenziano M, Catanese KA, et al. Bridge experience with long-term implantable left ventricular assist devices. Are they an alternative to transplantation? Circulation 1997;95:1844-1852.[Abstract/Free Full Text]
  5. McBride LR, Naunheim KS, Fiore AC, et al. Clinical experience with 111 Thoratec ventricular assist devices Ann Thorac Surg 1999;67:1233-1239.[Abstract/Free Full Text]
  6. Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices N Engl J Med 1998;339:1522-1533.[Free Full Text]
  7. Dew MA, Kormos RL, Winowich S, et al. Quality of life outcomes in left ventricular assist system inpatients and outpatients ASAIO J 1999;45:218-225.[Medline]
  8. Deshields TL, McDonough EM, Mannen RK, et al. Psychological and cognitive status before and after heart transplantation Gen Hosp Psychiatry 1996;18:625-629.
  9. van Dijk D, Nierich AP, Jansen EW, et al. Early outcome after off-pump versus on-pump coronary bypass surgeryresults from a randomized study. Circulation 2001;104:1761-1766.[Abstract/Free Full Text]
  10. Shapiro PA, Williams DL, Foray AT, et al. Psychosocial evaluation and prediction of compliance problems and morbidity after heart transplantation Transplantation 1995;60:1462-1466.[Medline]
  11. Moskowitz AJ, Weinberg AD, Oz MC, et al. Quality of life with an implanted left ventricular assist device Ann Thorac Surg 1997;64:1764-1769.[Abstract/Free Full Text]
  12. Grady KL, Meyer P, Mattea A, et al. Improvement in quality of life outcomes 2 weeks after left ventricular assist device implantation J Heart Lung Transplant 2001;20:657-669.[Medline]
  13. Dew MA, Kormos RL, Winowich S, et al. Quality of life outcomes after heart transplantation in individuals bridged to transplant with ventricular assist devices J Heart Lung Transplant 2001;20:1199-1212.[Medline]
  14. Phipps L. Psychiatric aspects of heart transplantation Can J Psychiatry 1991;36:563-568.[Medline]
  15. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure Circulation 1991;83:778-786.[Abstract/Free Full Text]
  16. Singer MA, Hopman WM, MacKenzie TA. Physical functioning and mental health in patients with chronic medical conditions Qual Life Res 1999;8:687-691.[Medline]
  17. Bunzel B, Wollenek G. Heart transplantationare there psychosocial predictors for clinical success of surgery?. Thorac Cardiovasc Surg 1994;42:103-107.[Medline]
  18. Dew MA, Simmons RG, Roth LH, et al. Psychosocial predictors of vulnerability to distress in the year following heart transplantation Psychol Med 1994;24:929-945.[Medline]
  19. Schall RR, Petrucci RJ, Brozena SC, et al. Cognitive function in patients with symptomatic dilated cardiomyopathy before and after cardiac transplantation J Am Coll Cardiol 1989;14:1666-1672.[Abstract]
  20. Zuccala G, Onder G, Pedone C, et al. On behalf of the GIFA (SIGG-ONLUS) Investigators Cognitive dysfunction as a major determinant of disability in patients with heart failureresults from a multicentre survey. J Neurol Neurosurg Psychiatry 2001;70:109-112.[Abstract/Free Full Text]
  21. Nussbaum PD, Allender P, Copeland P. Verbal learning in cardiac transplant candidatesa preliminary report. Intern J Rehab Health 1995;1:5-12.
  22. Bornstein RA, Starling RC, Myerowitz PD, et al. Neuropsychological function in patients with end-stage heart failure before and after cardiac transplantation Acta Neurol Scand 1995;91:260-265.[Medline]
  23. Woo MA, Macey PM, Fonaro GC, Hamilton MA, Harper RM. Regional gray matter loss in heart failure J Appl Physiol 2003;95:8750-8757.
  24. Almeida OP, Flicker L. The mind of the failing hearta systematic review of the asociation between congestive heart failure and cognitive functioning. Intern Med 2001;31:290-295.
  25. Russell EW. A multiple scoring method for the assessment of complex memory functions J Consult Clin Psychol 1975;43:800-809.
  26. Benton AL. Revised visual retention test, clinical and experimental applications. New York: Psychological Corporation; 1974.
  27. Rey A. L'examen Clinique en Psycholologie. Paris: Presses Universitaires de France; 1964.
  28. Reitan RM. The Halstead-Reitan neuropsychological test battery. Tucson, AZ: Neuropsychology Press; 1985.
  29. Zucalla G, Onder G, Pedone C, et al. Cognitive dysfunction as a major determinant of disability in patients with heart failureresults from a multicentre survey. J Neurol Neurosurg Psychiatry 2001;70:109-112.[Abstract/Free Full Text]
  30. Zucalla G, Catetel C, Manes-Gravina E, et al. Left ventricle dysfunctiona clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry 1997;63:509-512.[Abstract/Free Full Text]
  31. Katz SD, Marantz PR, Biasucci L, et al. Low incidence of stroke in ambulatory patients with heart failurea prospective study. Am Heart J 1993;126:141-146.[Medline]
  32. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer typea pathoanatomical study. Ann Neurol 1993;19:253-262.
  33. Jessup M, Pina I. Is it important to examine gender differences in the epidemiology and outcome of severe heart failure? J Thorac Cardiovasc Surg 2004;127:1247-1252.[Free Full Text]
  34. Zucalla G, Onder G, Pedone C, et al. Hypotension and cognitive impairmentselection association in patients with heart failure. Neurology 2001;57:1986-1992.[Abstract/Free Full Text]
  35. Aronson D, Burger AJ. Gender-related differences in modulaton of heart rate in patients with congestive heart failure J Cardiovasc Electrophysiol 2000;11:1071-1077.[Medline]
  36. Woo M, Macey P, Fonarow G, et al. Regional brain gray matter loss in heart failure J Appl Physiol 2003;95:677-687.[Abstract/Free Full Text]
  37. Guerra S, Leri A, Wang X, et al. Myocyte death in the failing human heart is gender dependent Circ Res 1999;85:856-866.[Abstract/Free Full Text]
  38. Communal C, Singh K, Pimentel DR, et al. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway Circulation 1998;98:1329-1334.[Abstract/Free Full Text]
  39. US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiologic Health Assessments of neurologic/neurocognitive function. guidance for industry and FDA reviewers. 2003(in preparation).
  40. Meilniczuk L, Mussivand T, Davies R, et al. Patient selection for left ventricular assist devices Artific Organs 2004;28:152-157.



This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
R. L.C. Vogels, P. Scheltens, J. M. Schroeder-Tanka, and H. C. Weinstein
Cognitive impairment in heart failure: A systematic review of the literature
Eur J Heart Fail, May 1, 2007; 9(5): 440 - 449.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Anne Carter
Louis E. Samuels
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petrucci, R. J.
Right arrow Articles by Narula, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petrucci, R. J.
Right arrow Articles by Narula, J.
Related Collections
Right arrow Mechanical Circulatory Assistance

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS